Skip to main content
2023 Guide to Patient Support Services


2023 PSS Guide

Exelixis Access Services


Exelixis Access Services (EASE) includes programs designed to support patients who are prescribed Exelixis oncology drugs Cabometyx or Cometriq (Table).

EASE Programs

The EASE programs are drug-specific and provide financial, access, and reimbursement support for eligible patients.

Click here to enroll your patients who have been prescribed Cabometyx. Click here to enroll your patients who have been prescribed Cometriq.

Cabometyx 30-Day Free Trial Program

The 30-Day Free Trial Program provides a free trial to help new Cabometyx patients start treatment quickly, regardless of insurance type. A 30-day additional supply may be available to patients with a payer decision delay of ≥5 days.

  • Limited to on-label indications
  • Must be new prescription
  • Restrictions and eligibility rules apply.

Cabometyx Dose Exchange Program

The Dose Exchange program provides a free 15-tablet supply of Cabometyx in the lower dose to help patients who require a dose reduction.

  • Patients are required to return any unused product
  • Additional restrictions and eligibility rules apply.

EASE Co-Pay Program

Eligible, commercially insured patients may pay as little as $0 per month for Cabometyx or Cometriq. Annual and transaction limits apply.

EASE Patient Assistance Program

Eligible patients who are uninsured or are insured but cannot afford the cost of the medication may receive Cabometyx or Cometriq free of charge.

TABLE Exelixis Oncology Drugs

Patient support programs

Cabometyx (cabozantinib) tablets
Patient support programs

Cometriq (cabozantinib) capsules
Treatment of progressive, metastatic medullary thyroid cancer
Patient support programs

Cabometyx (cabozantinib) tablets Indications

Treatment of patients with advanced renal-cell carcinoma (RCC); first-line treatment of patients with advanced RCC in combination with nivolumab; treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib; treatment of adult and pediatric patients aged ≥12 years with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor–targeted therapy and who are radioactive iodine-refractory or ineligible

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"